Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
M. Asayama
Institution:
Saitama Cancer Center
Observed institution:
Saitama Cancer Center
ORCID:
0009-0007-2763-1661
Observed ORCID:
0009-0007-2763-1661
OpenAlex ID:
A5041246531
PRABITAS study design: a pragmatic, randomized phase III trial of bi-weekly versus conventional trifluridine/tipiracil plus bevacizumab for metastatic colorectal cancer
2024
·
T. Sakakida
, T. Masuishi
, et al.
·
ESMO Gastrointestinal Oncology
·
4
PDF
446TiP Randomized phase III study of bi-weekly trifluridine/tipiracil (FTD/TPI) plus bevacizumab (BEV) vs. FTD/TPI for chemorefractory metastatic colorectal cancer (mCRC): ROBiTS/JCOG2014
2022
·
K. Yamazaki
, H. Satake
, et al.
·
Annals of Oncology
·
2
770P Impact of ctDNA testing on decision-making for adjuvant chemotherapy in colorectal cancer: A prospective multicenter study
2025
·
S. Fukuoka
, H. Osumi
, et al.
·
Annals of Oncology
528P The randomized phase III study of bi-weekly trifluridine/tipiracil (FTD/TPI) plus bevacizumab (BEV) vs. FTD/TPI monotherapy for chemorefractory metastatic colorectal cancer (mCRC): 1-year follow-up updated data from JCOG2014 (ROBiTS)
2024
·
Y. Suwa
, H. Satake
, et al.
·
Annals of Oncology
PDF
Show more works
View as search
Works count:
4
Citation count:
6
H-index:
2
I10-index:
Year
Topic
Type